Nasdaq26d
Biogen Inc. Announces FDA and EMA Acceptance of Higher Dose Regimen for Nusinersen in Spinal Muscular Atrophy
Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...
Hosted on MSN5d
Royalty Pharma pays $250m for rights to Biogen’s lupus drug
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
Business Insider26d
Biogen announces FDA, EMA accepted applications for higher dose of nusinersen
Biogen (BIIB) announced that the U.S. Food ... has validated the application for a higher dose regimen of nusinersen for spinal muscular atrophy, SMA. The higher dose regimen of nusinersen ...
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biogen faces revenue challenges as Leqembi sales lag projections. Investors watch its pipeline expansion and strategic moves amid upcoming Q4 earnings.
The Pharma Letter6d
Biogen beats on earnings but guidance falls short
Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...
NBC New York6d
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...
Yahoo Finance6d
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Biotech giant Biogen Inc (NASDAQ:BIIB ... marketing applications seeking approval for a higher dose regimen of nusinersen for spinal muscular atrophy (SMA). The higher dose regimen of nusinersen ...